Ebola intelligence brief.
Confirmed WHO facts
WHO's daily epidemiological table reports 7,279 confirmed cases and 3,512 confirmed deaths across the Democratic Republic of the Congo, Uganda and France. The total combines Democratic Republic of the Congo data through 13 September, Uganda data through 21 July and France data through 6 July. Compared with the previous table through 10 September, this is an arithmetic increase of 236 confirmed cases and 112 confirmed deaths over three reporting days. The Democratic Republic of the Congo accounts for 7,258 cases and 3,510 deaths; the daily table reports 1,745 recoveries across the three countries. DON617 reports that the outbreak had expanded to 61 health zones across six provinces, with 51 health zones in five provinces reporting at least one case in the preceding 21 days. WHO maintains its risk assessment at very high for the Democratic Republic of the Congo, high for neighbouring countries sharing land borders, and low for the rest of the African Region and globally.
WHO says daily figures for the Democratic Republic of the Congo may be revised retrospectively, and the different country cut-off dates mean the combined total is not real time. The three-day differences are reporting-period comparisons, not measures of incidence or undetected burden. The suspected-case count decreased from 429 to 351 while confirmed totals increased, illustrating that categories can change through verification and data reconciliation. DON617 states that part of the wider increase may reflect stronger surveillance, expanded laboratory testing, improved diagnostic capacity and reconciliation of previously unreported data, while continued growth also reflects sustained community transmission and geographic expansion. WHO reports that 2,007 people had received Ervebo across six health zones as of 6 September, but states that protection against Bundibugyo virus in humans remains unknown and recommends use within research protocols; this count is not evidence of vaccine effectiveness, routine authorisation or individual protection.
Vision Biotechnology response lens
- Re-map specimen referral and confirmation capacity against the 61 affected health zones, with surge routes for the 51 zones reporting recent activity and for cross-border risk areas.
- Maintain validated molecular workflows, trained personnel, biosafety controls, documented quality systems, external quality assurance and clear rules for invalid, discordant and referred results.
- Route suspected-case testing, confirmation, result release and research-linked records only through authorised national and international public-health pathways.
- Plan complete testing episodes—not kit counts alone—including controls, collection materials, compliant transport, cold-chain interfaces, lot traceability, instrument uptime and replenishment buffers.
- Treat localisation as controlled capacity building: method transfer, supplier qualification, training, change control, regulatory readiness and network-wide quality oversight must accompany equipment or production deployment.